Figure 3.

The odds ratio of each adverse event in EGFR-TKIs. The graphs show the forest plots for gefitinib (A), and for erlotinib (B). In the gefitinib cohort, reduced function was associated with an increased risk of rash (*p = 0.03). In the erlotinib cohort, there were no associations between any adverse events and CYP2D6 phenotypes.

Suzumura et al. BMC Cancer 2012 12:568   doi:10.1186/1471-2407-12-568
Download authors' original image